Ambit Biosciences

Ambit completes $25M financing for AML drug

Wednesday, November 7, 2012

Ambit Biosciences, a privately held biopharmaceutical company based in San Diego, has closed the first $25 million tranche of a new $50 million preferred stock financing to support continued advancement of its lead drug candidate, quizartinib, for the treatment of acute myeloid leukemia (AML).

[Read More]